Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIVAR milrinone infusion for vasospasm after aneurysmal subarachnoid hemorrhage
2024-515994-83-00Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Jan 2026
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cloxacillin in cerebral vasospasm (2 arms), sponsored by Centre Hospitalier Universitaire d'Angers. Primary endpoint: Good functional outcome at 3 months. Started Jan 2026; status: completed.
02
Drugs
cloxacillin
03
Conditions
cerebral vasospasm
Beyond the preview
Go deeper on 2024-515994-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515994-83-00.